ArticleDer Radiologe2013
[Contrast agents in radiology: current agents approved, recommendations, and safety aspects].
Article in Der Radiologe, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association between acute adverse reactions to iodinated contrast media and anxiety in patients undergoing contrast-enhanced CT examination.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- [Success, satisfaction and improvement of informed consents for computed tomography : A survey among patients and physicians].Der Radiologe · 2020Article
- [Optimized detection and characterization of liver metastases : The role of current MRI contrast agents].Der Radiologe · 2017Review
- [Indications for contrast media].Der Radiologe · 2013Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The manuscript summarizes current approved contrast media and their indications. Contrast agents that are discussed include iodinated contrast agents, magnetic resonance (MR) contrast agents, and ultrasound contrast agents. Allergic and non-allergic renal adverse events are described. The clinical issue of metformin and the administration of contrast agents are updated. Nephrogenic systemic fibrosis (NSF) is discussed and safety issues of available MR contrast agents are analyzed. The most recent changes in European Society of Urogenital Radiology (ESUR) guidelines are also presented.
Indexed as
Identifiers
23340684What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.